1
|
Blum K, Bowirrat A, Baron D, Elman I, Makale MT, Cadet JL, Thanos PK, Hanna C, Ahmed R, Gondre-Lewis MC, Dennen CA, Braverman ER, Soni D, Carney P, Khalsa J, Modestino EJ, Barh D, Bagchi D, Badgaiyan RD, McLaughlin T, Cortese R, Ceccanti M, Murphy KT, Gupta A, Makale MT, Sunder K, Gold MS. Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences. GENE & PROTEIN IN DISEASE 2024; 3:10.36922/gpd.1966. [PMID: 38766604 PMCID: PMC11100097 DOI: 10.36922/gpd.1966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2024]
Abstract
The D2 dopamine receptor (DRD2) gene has garnered substantial attention as one of the most extensively studied genes across various neuropsychiatric disorders. Since its initial association with severe alcoholism in 1990, particularly through the identification of the DRD2 Taq A1 allele, numerous international investigations have been conducted to elucidate its role in different conditions. As of February 22, 2024, there are 5485 articles focusing on the DRD2 gene listed in PUBMED. There have been 120 meta-analyses with mixed results. In our opinion, the primary cause of negative reports regarding the association of various DRD2 gene polymorphisms is the inadequate screening of controls, not adequately eliminating many hidden reward deficiency syndrome behaviors. Moreover, pleiotropic effects of DRD2 variants have been identified in neuropsychologic, neurophysiologic, stress response, social stress defeat, maternal deprivation, and gambling disorder, with epigenetic DNA methylation and histone post-translational negative methylation identified as discussed in this article. There are 70 articles listed in PUBMED for DNA methylation and 20 articles listed for histone methylation as of October 19, 2022. For this commentary, we did not denote DNA and/or histone methylation; instead, we provided a brief summary based on behavioral effects. Based on the fact that Blum and Noble characterized the DRD2 Taq A1 allele as a generalized reward gene and not necessarily specific alcoholism, it now behooves the field to find ways to either use effector moieties to edit the neuroepigenetic insults or possibly harness the idea of potentially removing negative mRNA-reduced expression by inducing "dopamine homeostasis."
Collapse
Affiliation(s)
- Kenneth Blum
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel
- Division of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University of the Health Sciences, Pomona, CA, United States of America
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
- Department of Psychiatry, University of Vermont, Burlington, VT 05405, United States of America
- Department of Psychiatry, Wright University Boonshoft School of Medicine, Dayton, OH, United States of America
- Division of Nutrigenomics, The Kenneth Blum Behavioral Neurogenetic Institute, Austin, TX United States of America
- Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India
- Department of Nutrigenomic Research, Victory Nutrition International, Inc., Bonita Springs, FL, United States of America
- Division of Personalized Neuromodulation Research, Sunder Foundation, Palm Springs, CA, United States of America
| | - Abdalla Bowirrat
- Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel
| | - David Baron
- Division of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University of the Health Sciences, Pomona, CA, United States of America
| | - Igor Elman
- Division of Personalized Neuromodulation Research, Sunder Foundation, Palm Springs, CA, United States of America
- Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, United States of America
| | - Milan T. Makale
- Department of Radiation Medicine and Applied Sciences, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, United States of America
| | - Jean Lud Cadet
- Molecular Neuropsychiatry Research Branch, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD., United States of America
| | - Panayotis K. Thanos
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, United States of America; Department of Psychology, State University of New York at Buffalo, Buffalo, NY., United States of America
| | - Colin Hanna
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, United States of America; Department of Psychology, State University of New York at Buffalo, Buffalo, NY., United States of America
| | - Rania Ahmed
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, United States of America; Department of Psychology, State University of New York at Buffalo, Buffalo, NY., United States of America
| | - Marjorie C. Gondre-Lewis
- Department of Anatomy, Howard University College of Medicine, and Developmental Neuropsychopharmacology Laboratory, Howard University College of Medicine, Washington D.C., United States of America
| | - Catherine A. Dennen
- Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, United States of America
| | - Eric R. Braverman
- Division of Nutrigenomics, The Kenneth Blum Behavioral Neurogenetic Institute, Austin, TX United States of America
| | - Diwanshu Soni
- Division of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University of the Health Sciences, Pomona, CA, United States of America
| | - Paul Carney
- Division Pediatric Neurology, University of Missouri, School of Medicine, Columbia, MO., United States of America
| | - Jag Khalsa
- Department of Microbiology, Immunology and Tropical Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, United States of America
| | - Edward J. Modestino
- Department of Psychology, Curry College, Milton, MA., United States of America
| | - Debmalya Barh
- Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India
- Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Debasis Bagchi
- Department of Pharmaceutical Sciences, Texas Southern University College of Pharmacy and Health Sciences, Houston, TX, United States of America
| | - Rajendra D. Badgaiyan
- Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland OH., 44106, USA and Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY, United States of America
| | - Thomas McLaughlin
- Division of Nutrigenomics, The Kenneth Blum Behavioral Neurogenetic Institute, Austin, TX United States of America
| | - Rene Cortese
- Department of Child Health – Child Health Research Institute, & Department of Obstetrics, Gynecology and Women’s Health School of Medicine, University of Missouri, MO, United States of America
| | - Mauro Ceccanti
- Alcohol Addiction Program, Latium Region Referral Center, Sapienza University of Rome, Roma, Italy
| | - Kevin T. Murphy
- Division of Personalized Neuromodulation and Patient Care, PeakLogic, LLC, Del Mar, CA, United States of America
| | - Ashim Gupta
- Future Biologics, Lawrenceville, Georgia, 30043, United States of America
| | - Miles T. Makale
- Department of Psychology, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, United States of America
| | - Keerthy Sunder
- Division of Personalized Neuromodulation Research, Sunder Foundation, Palm Springs, CA, United States of America
- Department of Psychiatry, UC Riverside School of Medicine, Riverside, CA, United States of America
| | - Mark S. Gold
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States of America
| |
Collapse
|
2
|
Kang Y, Zhang Y, Huang K, Wang Z. Association of dopamine-based genetic risk score with dynamic low-frequency fluctuations in first-episode drug-naïve schizophrenia. Brain Imaging Behav 2023; 17:584-594. [PMID: 37382826 DOI: 10.1007/s11682-023-00786-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/11/2023] [Indexed: 06/30/2023]
Abstract
Alterations in dynamic intrinsic brain activity and signaling of neurotransmitters, such as dopamine, have been independently detected in schizophrenia patients. Yet, it remains unclear whether the dopamine genetic risk variants have association with brain intrinsic activity. We aimed to investigate the schizophrenia-specific dynamic amplitude of low frequency fluctuation (dALFF) altered pattern, and its association with dopamine genetic risk score in first-episode drug-naïve schizophrenia (FES). Fifty-two FES and 51 healthy controls were included. A sliding-window method based on the dALFF was adopted to estimate the dynamic alterations in intrinsic brain activity. Subjects were genotyped, and a genetic risk score (GRS), which combined the additive effects of ten risk genotypes from five dopamine-related genes, was calculated. We used the voxel-wise correlation analysis to explore the association of dopamine-GRS with dALFF. FES showed significantly increased dALFF left medial prefrontal cortex and significantly decreased dALFF in the right posterior cingulate cortex compared with healthy controls. Greater dopamine GRS in FES was associated with higher dALFF in the left middle frontal gyrus and left inferior parietal gyrus. Our findings indicate that cumulative dopamine genetic risk is associated with a known imaging phenotype for schizophrenia.
Collapse
Affiliation(s)
- Yafei Kang
- Shaanxi Provincial Key Research Center of Child Mental and Behavioral Health, School of Psychology, Shaanxi Normal University, Xi'an, China
| | - Youming Zhang
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, China
| | - Kexin Huang
- West China Biomedical Big Data Centre, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
| | - Zhenhong Wang
- Shaanxi Provincial Key Research Center of Child Mental and Behavioral Health, School of Psychology, Shaanxi Normal University, Xi'an, China.
| |
Collapse
|
3
|
Petty A, Glass LJ, Rothmond DA, Purves-Tyson T, Sweeney A, Kondo Y, Kubo S, Matsumoto M, Weickert CS. Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia. J Neuroinflammation 2022; 19:188. [PMID: 35841099 PMCID: PMC9287858 DOI: 10.1186/s12974-022-02541-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 06/22/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND There is growing evidence that neuroinflammation may contribute to schizophrenia neuropathology. Elevated pro-inflammatory cytokines are evident in the midbrain from schizophrenia subjects, findings that are driven by a subgroup of patients, characterised as a "high inflammation" biotype. Cytokines trigger the release of antibodies, of which immunoglobulin G (IgG) is the most common. The level and function of IgG is regulated by its transporter (FcGRT) and by pro-inflammatory IgG receptors (including FcGR3A) in balance with the anti-inflammatory IgG receptor FcGR2B. Testing whether abnormalities in IgG activity contribute to the neuroinflammatory abnormalities schizophrenia patients, particularly those with elevated cytokines, may help identify novel treatment targets. METHODS Post-mortem midbrain tissue from healthy controls and schizophrenia cases (n = 58 total) was used to determine the localisation and abundance of IgG and IgG transporters and receptors in the midbrain of healthy controls and schizophrenia patients. Protein levels of IgG and FcGRT were quantified using western blot, and gene transcript levels of FcGRT, FcGR3A and FcGR2B were assessed using qPCR. The distribution of IgG in the midbrain was assessed using immunohistochemistry and immunofluorescence. Results were compared between diagnostic (schizophrenia vs control) and inflammatory (high vs low inflammation) groups. RESULTS We found that IgG and FcGRT protein abundance (relative to β-actin) was unchanged in people with schizophrenia compared with controls irrespective of inflammatory subtype. In contrast, FcGRT and FcGR3A mRNA levels were elevated in the midbrain from "high inflammation" schizophrenia cases (FcGRT; p = 0.02, FcGR3A; p < 0.0001) in comparison to low-inflammation patients and healthy controls, while FcGR2B mRNA levels were unchanged. IgG immunoreactivity was evident in the midbrain, and approximately 24% of all individuals (control subjects and schizophrenia cases) showed diffusion of IgG from blood vessels into the brain. However, the intensity and distribution of IgG was comparable across schizophrenia cases and control subjects. CONCLUSION These findings suggest that an increase in the pro-inflammatory Fcγ receptor FcGR3A, rather than an overall increase in IgG levels, contribute to midbrain neuroinflammation in schizophrenia patients. However, more precise information about IgG-Fcγ receptor interactions is needed to determine their potential role in schizophrenia neuropathology.
Collapse
Affiliation(s)
- A Petty
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia
| | - L J Glass
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- Centre for Immunology and Allergy Research, Westmead Institute of Medical Research, The University of Sydney, Sydney, Australia
| | - D A Rothmond
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
| | - T Purves-Tyson
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia
| | - A Sweeney
- NSW Brain Tissue Resource Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Y Kondo
- Astellas Research Institute of America LLC, San Diego, CA, 92121, USA
| | - S Kubo
- Astellas Pharma Inc., Tsukuba, Ibaraki, 305-8585, Japan
| | - M Matsumoto
- Astellas Research Institute of America LLC, San Diego, CA, 92121, USA
| | - C Shannon Weickert
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia.
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia.
- Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, NY, 13210, USA.
| |
Collapse
|
4
|
Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. Mol Psychiatry 2022; 27:3247-3261. [PMID: 35618883 PMCID: PMC9708553 DOI: 10.1038/s41380-022-01554-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 03/24/2022] [Accepted: 03/25/2022] [Indexed: 11/08/2022]
Abstract
Presynaptic increase in striatal dopamine is the primary dopaminergic abnormality in schizophrenia, but the underlying mechanisms are not understood. Here, we hypothesized that increased expression of endogenous GDNF could induce dopaminergic abnormalities that resemble those seen in schizophrenia. To test the impact of GDNF elevation, without inducing adverse effects caused by ectopic overexpression, we developed a novel in vivo approach to conditionally increase endogenous GDNF expression. We found that a 2-3-fold increase in endogenous GDNF in the brain was sufficient to induce molecular, cellular, and functional changes in dopamine signalling in the striatum and prefrontal cortex, including increased striatal presynaptic dopamine levels and reduction of dopamine in prefrontal cortex. Mechanistically, we identified adenosine A2a receptor (A2AR), a G-protein coupled receptor that modulates dopaminergic signalling, as a possible mediator of GDNF-driven dopaminergic abnormalities. We further showed that pharmacological inhibition of A2AR with istradefylline partially normalised striatal GDNF and striatal and cortical dopamine levels in mice. Lastly, we found that GDNF levels are increased in the cerebrospinal fluid of first episode psychosis patients, and in post-mortem striatum of schizophrenia patients. Our results reveal a possible contributor for increased striatal dopamine signalling in a subgroup of schizophrenia patients and suggest that GDNF-A2AR crosstalk may regulate dopamine function in a therapeutically targetable manner.
Collapse
|
5
|
Nekrosius D, Kaminskaite M, Jokubka R, Pranckeviciene A, Lideikis K, Tamasauskas A, Bunevicius A. Association of COMT Val 158Met Polymorphism With Delirium Risk and Outcomes After Traumatic Brain Injury. J Neuropsychiatry Clin Neurosci 2020; 31:298-305. [PMID: 31046593 DOI: 10.1176/appi.neuropsych.18080195] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The authors investigated the association of the catechol-o-methyltransferase (COMT) gene Val158Met polymorphism with delirium risk and functional and cognitive outcomes among patients with complicated mild to moderate traumatic brain injury (TBI). METHODS In a prospective observational cohort study, patients were monitored for occurrence of delirium during the first 4 days of admission by using the Confusion Assessment Method. Functional and cognitive outcomes were evaluated with the Glasgow Outcome on Discharge Scale and the Montreal Cognitive Assessment test, respectively. Eighty-nine patients were included in the study; of these, 17 (19%) were diagnosed with delirium. RESULTS The COMT Val158/Val158 polymorphism was associated with increased risk of delirium in multivariable regression analyses adjusted for alcohol misuse, history of neurological disorder, age, and admission Glasgow Coma Scale score (odds ratio=4.57, 95% CI=1.11, 18.9, p=0.036). The COMT Met158 allele was associated with better functional outcomes in univariate analysis (odds ratio=2.82, 95% CI=1.10, 7.27, p=0.031) but not in multivariable analysis (odds ratio=2.33, 95% CI=0.89, 6.12, p=0.085). Cognitive outcomes were not associated with the COMT Val158Met polymorphism in univariate regression analysis (p=0.390). Delirium was a significant predictor of worse functional and cognitive outcomes in multivariable regression analyses adjusted for other risk factors (odds ratio=0.04, 95% CI=0.01, 0.16, p<0.001, and β=-3.889, 95% CI=-7.55, -0.23, p=0.038, respectively). CONCLUSIONS The COMT genotype is important in delirium risk and functional outcomes of patients with mild to moderate TBI. Whether the COMT genotype is associated with outcomes through incident delirium remains to be determined in larger studies.
Collapse
Affiliation(s)
- Deividas Nekrosius
- The Lithuanian University of Health Sciences, Kaunas, Lithuania (Nekrosius, Lideikis); the Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania (Kaminskaite, Jokubka, Pranckeviciene, Tamasauskas, Bunevicius); and the Department of Neurosurgery at Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania (Tamasauskas, Bunevicius)
| | - Migle Kaminskaite
- The Lithuanian University of Health Sciences, Kaunas, Lithuania (Nekrosius, Lideikis); the Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania (Kaminskaite, Jokubka, Pranckeviciene, Tamasauskas, Bunevicius); and the Department of Neurosurgery at Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania (Tamasauskas, Bunevicius)
| | - Ramunas Jokubka
- The Lithuanian University of Health Sciences, Kaunas, Lithuania (Nekrosius, Lideikis); the Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania (Kaminskaite, Jokubka, Pranckeviciene, Tamasauskas, Bunevicius); and the Department of Neurosurgery at Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania (Tamasauskas, Bunevicius)
| | - Aiste Pranckeviciene
- The Lithuanian University of Health Sciences, Kaunas, Lithuania (Nekrosius, Lideikis); the Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania (Kaminskaite, Jokubka, Pranckeviciene, Tamasauskas, Bunevicius); and the Department of Neurosurgery at Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania (Tamasauskas, Bunevicius)
| | - Karolis Lideikis
- The Lithuanian University of Health Sciences, Kaunas, Lithuania (Nekrosius, Lideikis); the Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania (Kaminskaite, Jokubka, Pranckeviciene, Tamasauskas, Bunevicius); and the Department of Neurosurgery at Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania (Tamasauskas, Bunevicius)
| | - Arimantas Tamasauskas
- The Lithuanian University of Health Sciences, Kaunas, Lithuania (Nekrosius, Lideikis); the Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania (Kaminskaite, Jokubka, Pranckeviciene, Tamasauskas, Bunevicius); and the Department of Neurosurgery at Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania (Tamasauskas, Bunevicius)
| | - Adomas Bunevicius
- The Lithuanian University of Health Sciences, Kaunas, Lithuania (Nekrosius, Lideikis); the Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, Lithuania (Kaminskaite, Jokubka, Pranckeviciene, Tamasauskas, Bunevicius); and the Department of Neurosurgery at Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania (Tamasauskas, Bunevicius)
| |
Collapse
|
6
|
Ustundag MF, Ozcan H, Gencer AG, Yilmaz ED, Uğur K, Oral E, Bilici M. Nitric oxide, asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine levels in psychotic exacerbation of schizophrenia and bipolar disorder manic episode. Saudi Med J 2020; 41:38-45. [PMID: 31915793 PMCID: PMC7001079 DOI: 10.15537/smj.2020.1.24817] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Accepted: 12/04/2019] [Indexed: 01/03/2023] Open
Abstract
OBJECTIVES To examine the changes in nitric oxide (NO), asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-arginine levels in schizophrenia during acute psychotic exacerbation and in bipolar disorder during mania and to compare those changes to healthy controls. METHODS Thirty schizophrenia patients with acute psychotic exacerbation and 30 bipolar disorder patients with mania, who attended the Psychiatry Department, Erenköy Hospital for Mental and Nervous Diseases, Istanbul, Turkey, in 2010. Thirty healthy controls were included. The diagnosis was made using the Structured Clinical Interview for Axis I Disorders (SCID-I) interviews. Patients' demographic data were recorded, and NO, SDMA, L-arginine, and ADMA levels were studied. RESULTS Nitric oxide levels in schizophrenia patients were significantly lower than the control group. Nitric oxide levels in the bipolar group were lower than the control group but the difference was not statistically significant. The levels of SDMA, ADMA, and L-arginine were found to be significantly higher in schizophrenia and bipolar disorder patients than the control group. The disease duration was slightly negatively correlated with NO levels in bipolar patients. In schizophrenia patients, the disease severity was slightly positively correlated with NO levels. CONCLUSION Significant changes in NO, SDMA, ADMA, and L-arginine levels in schizophrenia and bipolar disorder patients suggest that NO and inhibitors of NO might be implicated in the neurobiology of schizophrenia and bipolar disorder.
Collapse
Affiliation(s)
- Mehmet F Ustundag
- Department of Psychiatry, Erenköy Hospital for Mental and Nervous Diseases, Istanbul, Turkey. E-mail.
| | | | | | | | | | | | | |
Collapse
|
7
|
Wells R, Jacomb I, Swaminathan V, Sundram S, Weinberg D, Bruggemann J, Cropley V, Lenroot RK, Pereira AM, Zalesky A, Bousman C, Pantelis C, Weickert CS, Weickert TW. The Impact of Childhood Adversity on Cognitive Development in Schizophrenia. Schizophr Bull 2020; 46:140-153. [PMID: 31050754 PMCID: PMC6942153 DOI: 10.1093/schbul/sbz033] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Childhood adversity, such as physical, sexual, and verbal abuse, as well as neglect and family conflict, is a risk factor for schizophrenia. Such adversity can lead to disruptions of cognitive function during development, undermining intellectual capabilities and academic achievement. Schizophrenia is a neurodevelopmental disorder that is associated with cognitive impairments that may become evident during childhood. The Australian Schizophrenia Research Bank database comprises a large community cohort (N = 1169) in which we previously identified 3 distinct cognitive groups among people with schizophrenia: (1) Compromised, current, and estimated premorbid cognitive impairment; (2) Deteriorated, substantial decline from estimated premorbid function; and (3) Preserved, performing in the normal cognitive range without decline. The compromised group displayed the worst functional and symptom outcomes. Here, we extend our previous work by assessing the relationship among these categories of cognitive abilities and reported childhood adversity in 836 patients and healthy controls. Exploratory factor analysis of the Childhood Adversity Questionnaire revealed 3 factors (lack of parental involvement; overt abuse; family breakdown and hardship). People with schizophrenia reported significantly more childhood adversity than healthy controls on all items and factors. People with schizophrenia in the compromised group reported significantly more lack of parental involvement and family breakdown and hardship and lower socioeconomic status than those in the deteriorated group. The cognitive groups were not related to family history of psychosis. These findings identify specific social and family factors that impact cognition, highlighting the important role of these factors in the development of cognitive and functional abilities in schizophrenia.
Collapse
Affiliation(s)
- Ruth Wells
- School of Psychiatry, University of New South Wales, Sydney, Australia,Neuroscience Research Australia, Randwick, Sydney, Australia
| | - Isabella Jacomb
- School of Psychiatry, University of New South Wales, Sydney, Australia,Neuroscience Research Australia, Randwick, Sydney, Australia
| | - Vaidy Swaminathan
- Department of Psychiatry, University of Melbourne, Parkville, Australia,Mental Health Program, Monash Medical Centre, Monash Health, Clayton, Australia,Schizophrenia Research Institute, Sydney, Australia,Molecular Psychopharmacology Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Australia
| | - Suresh Sundram
- Department of Psychiatry, University of Melbourne, Parkville, Australia,Mental Health Program, Monash Medical Centre, Monash Health, Clayton, Australia,Molecular Psychopharmacology Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Australia,Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, Australia
| | - Danielle Weinberg
- School of Psychiatry, University of New South Wales, Sydney, Australia,Neuroscience Research Australia, Randwick, Sydney, Australia,Present address: Clinical Research Support Office, Childrens Hospital of Philadelphia, Philadelphia, PA
| | - Jason Bruggemann
- School of Psychiatry, University of New South Wales, Sydney, Australia,Neuroscience Research Australia, Randwick, Sydney, Australia
| | - Vanessa Cropley
- Department of Psychiatry, University of Melbourne, Parkville, Australia
| | - Rhoshel K Lenroot
- School of Psychiatry, University of New South Wales, Sydney, Australia,Neuroscience Research Australia, Randwick, Sydney, Australia,Schizophrenia Research Institute, Sydney, Australia,Present address: School of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM
| | - Avril M Pereira
- Department of Psychiatry, University of Melbourne, Parkville, Australia,Molecular Psychopharmacology Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, Australia
| | - Andrew Zalesky
- Department of Psychiatry, University of Melbourne, Parkville, Australia
| | - Chad Bousman
- Department of Psychiatry, University of Melbourne, Parkville, Australia,Present address: Department of Medical Genetics, Psychiatry, and Physiology & Pharmacology, University of Calgary, Alberta, Canada
| | - Christos Pantelis
- Department of Psychiatry, University of Melbourne, Parkville, Australia,Schizophrenia Research Institute, Sydney, Australia
| | - Cynthia Shannon Weickert
- School of Psychiatry, University of New South Wales, Sydney, Australia,Neuroscience Research Australia, Randwick, Sydney, Australia,Schizophrenia Research Institute, Sydney, Australia,Present address: Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York
| | - Thomas W Weickert
- School of Psychiatry, University of New South Wales, Sydney, Australia,Neuroscience Research Australia, Randwick, Sydney, Australia,Schizophrenia Research Institute, Sydney, Australia,To whom correspondence should be addressed; tel: +61-02-9399-1730, fax: +61-02-9399-1034, e-mail:
| |
Collapse
|
8
|
Laksono JP, Sumirtanurdin R, Dania H, Ramadhani FN, Perwitasari DA, Abdulah R, Barliana MI. Polymorphism of TPH2 Gene rs120074175 Is Not Associated with Risk Factors of Schizophrenia. JOURNAL OF PHARMACY AND BIOALLIED SCIENCES 2019; 11:S601-S604. [PMID: 32148370 PMCID: PMC7020838 DOI: 10.4103/jpbs.jpbs_216_19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Accepted: 11/01/2019] [Indexed: 12/25/2022] Open
Abstract
CONTEXT Polymorphism on tryptophan hydroxylase 2 (TPH2) gene rs120074175 can cause the synthesis of neurotransmitter serotonin in the brain to reduce up to 80%. Reduced serotonin in the brain can cause dopamine release to occur continuously. Excess dopamine in the brain may cause positive symptom of schizophrenia. AIM The aim of this study was to investigate the genotype distribution of TPH2 rs120074175 gene on patients with schizophrenia at Prof. Dr. Soerojo Magelang Psychiatric Hospital, Indonesia, and the relationship between the genetic polymorphism of the TPH2 rs120074175 gene against risk factors of schizophrenia. SETTINGS AND DESIGN This was a cross-sectional study. MATERIALS AND METHODS The method used was amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Whole blood from healthy subjects and patients with schizophrenia, Wizard genomic deoxyribonucleic acid (DNA) purification kit (Promega, Fitchburg, Wisconsin), PCR master mix (Promega), ARMS-PCR primers, ddH2O, agarose (Thermo Scientific, Seoul, South Korea), Tris, Acetic Acid, EDTA (TAE) 1X, ethidium bromide, loading dye 6×, and DNA ladder (Thermo Scientific) were the materials used. STATISTICAL ANALYSIS Hardy-Weinberg equilibrium and chi-square (χ2) tests were used. RESULTS The results showed that both groups (healthy subjects and patients with schizophrenia) at the Prof. Dr. Soerojo Magelang Psychiatric Hospital have a wild-type GG genotype (100%) without anyone having a mutant A allele. CONCLUSION TPH2 rs120074175 gene polymorphism was not associated with risk factors for schizophrenia.
Collapse
Affiliation(s)
- James P. Laksono
- Department Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia
| | - Riyadi Sumirtanurdin
- Department Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia
| | - Haafizah Dania
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia
- Departement of Pharmacology and Clinical Pharmacy Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
| | - Fitri N. Ramadhani
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia
| | - Dyah A. Perwitasari
- Departement of Pharmacology and Clinical Pharmacy Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia
| | - Rizky Abdulah
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia
- Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia
| | - Melisa I. Barliana
- Department Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia
- Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia
| |
Collapse
|
9
|
Xia Y, Pang H, Dou T, Wang P, Ge G. Interspecies comparison in the COMT-mediated methylation of 3-BTD. RSC Adv 2018; 8:16278-16284. [PMID: 35542223 PMCID: PMC9080226 DOI: 10.1039/c8ra01938j] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 04/18/2018] [Indexed: 12/26/2022] Open
Abstract
Catechol-O-methyltransferase (COMT) is a druggable biological target and COMT modulators have been widely applied in the treatment of various central and peripheral nervous system disorders. The interspecies differences of COMT were carefully investigated using 3-BTD (a newly developed fluorescent probe of COMT) methylation as the probe reaction, and liver S9 from humans and seven experimental animals including monkeys, dogs, mice, rats, minipigs, guinea pigs and New Zealand rabbits as the enzyme source. Metabolite profiling demonstrated that all the tested liver S9 samples from the different animals could catalyse 3-BTD methylation but displayed significant differences in reaction rate. Also, the differential effects of tolcapone (a potent inhibitor against COMT) on 3-BTD methylation among various species were observed. The apparent kinetic parameters and the maximum intrinsic clearances (Clint) for 3-BTD methylation in liver S9 from the different animals were determined, and the order of the Clint values for the formation of 3-BTD was RLS9 > DLS9 ≈ PLS9 > MLS9 > CyLS9 > RaLS9 > GpLS9 > HLS9. These findings are helpful for further exploring COMT-associated biological processes in animal models, as well as for developing therapeutic molecules that target COMT. The methylation behaviour of 3-BTD in liver S9 from eight different species was characterized with respect to the similarities and differences of their metabolic profiles, catalytic efficacy and inhibitory potency by a known chemical inhibitor.![]()
Collapse
Affiliation(s)
- Yangliu Xia
- Laboratory of Pharmacology & Toxicology
- School of Life Science and Medicine
- Dalian University of Technology
- Panjin 124221
- China
| | - Huilin Pang
- Laboratory of Pharmacology & Toxicology
- School of Life Science and Medicine
- Dalian University of Technology
- Panjin 124221
- China
| | - Tongyi Dou
- Laboratory of Pharmacology & Toxicology
- School of Life Science and Medicine
- Dalian University of Technology
- Panjin 124221
- China
| | - Ping Wang
- Shanghai University of Traditional Chinese Medicines
- Shanghai
- China
| | - Guangbo Ge
- Shanghai University of Traditional Chinese Medicines
- Shanghai
- China
| |
Collapse
|
10
|
Wang P, Xia YL, Zou LW, Qian XK, Dou TY, Jin Q, Li SY, Yu Y, Wang DD, Luo Q, Ge GB, Yang L. An Optimized Two-Photon Fluorescent Probe for Biological Sensing and Imaging of Catechol-O-Methyltransferase. Chemistry 2017; 23:10800-10807. [PMID: 28512752 DOI: 10.1002/chem.201701384] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Indexed: 01/10/2023]
Abstract
A practical two-photon fluorescent probe was developed for highly sensitive and selective sensing of the activities of catechol-O-methyltransferase (COMT) in complex biological samples. To this end, a series of 3-substituted 7,8-dihydroxycoumarins were designed and synthesized. Among them, 3-BTD displayed the best combination of selectivity, sensitivity, reactivity, and fluorescence response following COMT-catalyzed 8-O-methylation. The newly developed two-photon fluorescent probe 3-BTD can be used for determining the activities of COMT in complex biological samples and bio-imaging of endogenous COMT in living cells and tissue slices with good cell permeability, low cytotoxicity, and high imaging resolution. All these findings suggest that 3-BTD holds great promise for developing therapeutic molecules that target COMT, as well as for exploring COMT-associated biological processes and its biological functions in living systems. Furthermore, the strategy also sheds new light on the development of fluorescent probes for other conjugative enzymes.
Collapse
Affiliation(s)
- Ping Wang
- Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| | - Yang-Liu Xia
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P. R. China
| | - Li-Wei Zou
- Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| | - Xing-Kai Qian
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P. R. China
| | - Tong-Yi Dou
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P. R. China
| | - Qiang Jin
- Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| | - Shi-Yang Li
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P. R. China
| | - Yang Yu
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P. R. China
| | - Dan-Dan Wang
- Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| | - Qun Luo
- Beijing National Laboratory for Molecular Sciences, National Centre for Mass Spectrometry in Beijing, CAS Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China
| | - Guang-Bo Ge
- Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.,Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P. R. China
| | - Ling Yang
- Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China
| |
Collapse
|
11
|
Kindler J, Weickert CS, Schofield PR, Lenroot R, Weickert TW. Raloxifene increases prefrontal activity during emotional inhibition in schizophrenia based on estrogen receptor genotype. Eur Neuropsychopharmacol 2016; 26:1930-1940. [PMID: 27842943 DOI: 10.1016/j.euroneuro.2016.10.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2016] [Revised: 09/23/2016] [Accepted: 10/29/2016] [Indexed: 12/16/2022]
Abstract
People with schizophrenia show decreased prefrontal cortex (PFC) activity during emotional response inhibition, a cognitive process sensitive to hormonal influences. Raloxifene, a selective estrogen receptor modulator, binds estrogen receptor alpha (ESR-α), improves memory, attention and normalizes cortical and hippocampal activity during learning and emotional face recognition in schizophrenia. Here, we tested the extent to which raloxifene restores neuronal activity during emotional response inhibition in schizophrenia. Since genetic variation in estrogen receptor alpha (ESR-1) determines cortical ESR-α production and correlates with cognition, we also predicted that genetic ESR-1 variation would differentially relate to increased cortical activity by raloxifene administration. Thirty people with schizophrenia participated in a thirteen-week randomized, double-blind, placebo-controlled, cross-over adjunctive treatment trial of raloxifene administered at 120mg/day. Effects of raloxifene on brain activation were assessed based on ESR-1 genotype using functional magnetic resonance imaging during emotional word inhibition. Raloxifene increased PFC activity during inhibition of response to negative words and the raloxifene related increased PFC activity was greater in patients homozygous for ESR-1 rs9340799 AA relative to G carriers. Comparison to 23 healthy controls demonstrated that PFC activity of people with schizophrenia receiving raloxifene was more similar to controls than to their own brain activity during placebo. Estrogen receptor modulation by raloxifene restores PFC activity during emotional response inhibition in schizophrenia and ESR-1 genotype predicts degree of increased neural activity in response to raloxifene. While these preliminary results require replication, they suggest the potential for personalized pharmacotherapy using ESR-1 and estrogen receptor targeting compounds in schizophrenia.
Collapse
Affiliation(s)
- Jochen Kindler
- School of Psychiatry, University of New South Wales, Randwick, NSW 2031 Australia; Neuroscience Research Australia, Randwick, NSW 2031, Australia; University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, 3000 Bern 60, Switzerland
| | - Cynthia Shannon Weickert
- School of Psychiatry, University of New South Wales, Randwick, NSW 2031 Australia; Neuroscience Research Australia, Randwick, NSW 2031, Australia; Schizophrenia Research Institute, Randwick, NSW 2031 Australia
| | - Peter R Schofield
- Neuroscience Research Australia, Randwick, NSW 2031, Australia; Schizophrenia Research Institute, Randwick, NSW 2031 Australia; School of Medical Sciences, University of New South Wales, Randwick, Australia
| | - Rhoshel Lenroot
- School of Psychiatry, University of New South Wales, Randwick, NSW 2031 Australia; Neuroscience Research Australia, Randwick, NSW 2031, Australia; Schizophrenia Research Institute, Randwick, NSW 2031 Australia
| | - Thomas W Weickert
- School of Psychiatry, University of New South Wales, Randwick, NSW 2031 Australia; Neuroscience Research Australia, Randwick, NSW 2031, Australia; Schizophrenia Research Institute, Randwick, NSW 2031 Australia.
| |
Collapse
|
12
|
A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples. Mol Psychiatry 2016; 21:975-82. [PMID: 26347318 DOI: 10.1038/mp.2015.137] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Revised: 08/03/2015] [Accepted: 08/05/2015] [Indexed: 01/12/2023]
Abstract
The rs1076560 polymorphism of DRD2 (encoding dopamine receptor D2) is associated with alternative splicing and cognitive functioning; however, a mechanistic relationship to schizophrenia has not been shown. Here, we demonstrate that rs1076560(T) imparts a small but reliable risk for schizophrenia in a sample of 616 affected families and five independent replication samples totaling 4017 affected and 4704 unaffected individuals (odds ratio=1.1; P=0.004). rs1076560(T) was associated with impaired verbal fluency and comprehension in schizophrenia but improved performance among healthy comparison subjects. rs1076560(T) also associated with lower D2 short isoform expression in postmortem brain. rs1076560(T) disrupted a binding site for the splicing factor ZRANB2, diminished binding affinity between DRD2 pre-mRNA and ZRANB2 and abolished the ability of ZRANB2 to modulate short:long isoform-expression ratios of DRD2 minigenes in cell culture. Collectively, this work implicates rs1076560(T) as one possible risk factor for schizophrenia in the Han Chinese population, and suggests molecular mechanisms by which it may exert such influence.
Collapse
|
13
|
Vink M, de Leeuw M, Luykx JJ, van Eijk KR, van den Munkhof HE, van Buuren M, Kahn RS. DRD2 Schizophrenia-Risk Allele Is Associated With Impaired Striatal Functioning in Unaffected Siblings of Schizophrenia Patients. Schizophr Bull 2016; 42:843-50. [PMID: 26598739 PMCID: PMC4838092 DOI: 10.1093/schbul/sbv166] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
A recent Genome-Wide Association Study showed that the rs2514218 single nucleotide polymorphism (SNP) in close proximity to dopamine receptor D2 is strongly associated with schizophrenia. Further, an in silico experiment showed that rs2514218 has a cis expression quantitative trait locus effect in the basal ganglia. To date, however, the functional consequence of this SNP is unknown. Here, we used functional Magnetic resonance imaging to investigate the impact of this risk allele on striatal activation during proactive and reactive response inhibition in 45 unaffected siblings of schizophrenia patients. We included siblings to circumvent the illness specific confounds affecting striatal functioning independent from gene effects. Behavioral analyses revealed no differences between the carriers (n= 21) and noncarriers (n= 24). Risk allele carriers showed a diminished striatal response to increasing proactive inhibitory control demands, whereas overall level of striatal activation in carriers was elevated compared to noncarriers. Finally, risk allele carriers showed a blunted striatal response during successful reactive inhibition compared to the noncarriers. These data are consistent with earlier reports showing similar deficits in schizophrenia patients, and point to a failure to flexibly engage the striatum in response to contextual cues. This is the first study to demonstrate an association between impaired striatal functioning and the rs2514218 polymorphism. We take our findings to indicate that striatal functioning is impaired in carriers of the DRD2 risk allele, likely due to dopamine dysregulation at the DRD2 location.
Collapse
Affiliation(s)
- Matthijs Vink
- Department of Psychiatry, University Medical Center Utrecht, Brain Center Rudolf Magnus, Utrecht, The Netherlands;
| | - Max de Leeuw
- Department of Psychiatry, University Medical Center Utrecht, Brain Center Rudolf Magnus, Utrecht, The Netherlands;,both authors contributed equally
| | - Jurjen J. Luykx
- Department of Psychiatry, University Medical Center Utrecht, Brain Center Rudolf Magnus, Utrecht, The Netherlands
| | - Kristel R. van Eijk
- Department of Psychiatry, University Medical Center Utrecht, Brain Center Rudolf Magnus, Utrecht, The Netherlands
| | - Hanna E. van den Munkhof
- Department of Psychiatry, University Medical Center Utrecht, Brain Center Rudolf Magnus, Utrecht, The Netherlands
| | - Mariët van Buuren
- Department for Cognitive Neuroscience, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - René S. Kahn
- Department of Psychiatry, University Medical Center Utrecht, Brain Center Rudolf Magnus, Utrecht, The Netherlands
| |
Collapse
|